Dashboard
Manage Tickers

CSTL


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

castle-biosciences-announced-the-publication-of-a-new-study-showing-that-decisiondx-melanoma-can-precisely-predict-sentinel-lymph-node-positivity-risk-to-help-guide-risk-aligned-sentinel-lymph-node-biopsy-decisions
Castle Biosciences Announced The Publicati...
09/11/2024 11:05:53

castle-biosciences-announced-publication-of-a-new-study-in-future-oncology-further-substantiating-use-of-its-decisiondx-scc-test-in-guiding-patient-selection-and-decision-making-related-to-the-use-of-art-in-patients-with-high-risk-cutaneous-squamous-cell-carcinoma
Castle Biosciences Announced Publication O...
09/05/2024 11:05:49

yum-china-posts-upbeat-earnings-joins-clear-secure-tg-therapeutics-bioventus-and-other-big-stocks-moving-higher-on-tuesday
Yum China Posts Upbeat Earnings, Joins Cle...
08/06/2024 15:47:18

stephens--co-reiterates-overweight-on-castle-biosciences-maintains-37-price-target
Stephens & Co. Reiterates Overweight on Ca...
08/06/2024 15:44:26

Stephens & Co. analyst Mason Carrico reiterates Castle Biosciences (NASDAQ:CSTL) with a Overweight and maintains $37 pri...

baird-maintains-outperform-on-castle-biosciences-raises-price-target-to-37
Baird Maintains Outperform on Castle Biosc...
08/06/2024 10:44:51

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...

castle-biosciences-increases-fy24-revenue-from-255m-267m-to-275m-300m-vs-260395m-est
Castle Biosciences Increases FY24 Revenue ...
08/05/2024 20:59:31

castle-biosciences-q2-2024-gaap-eps-031-beats-028-estimate-sales-87002m-beat-69341m-estimate
Castle Biosciences Q2 2024 GAAP EPS $0.31 ...
08/05/2024 20:13:04

Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $(...

on-semiconductor-posts-upbeat-earnings-joins-oil-states-international-commscope-holding-and-other-big-stocks-moving-higher-on-monday
ON Semiconductor Posts Upbeat Earnings, Jo...
07/29/2024 15:09:55

top-5-health-care-stocks-that-may-explode-in-july
Top 5 Health Care Stocks That May Explode ...
07/08/2024 12:40:10

why-nio-shares-are-trading-lower-by-over-8-here-are-other-stocks-moving-in-fridays-mid-day-session
Why NIO Shares Are Trading Lower By Over 8...
07/05/2024 16:59:40

Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has res...

baird-maintains-outperform-on-castle-biosciences-maintains-34-price-target
Baird Maintains Outperform on Castle Biosc...
07/05/2024 16:53:18

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and maintains $34 price target.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
06/19/2024 20:30:52

castle-biosciences-presents-new-data-highlighting-use-of-decisiondx-melanoma-to-identify-early-stage-melanoma-patients-at-high-risk-of-metastasis-to-the-central-nervous-system-to-prompt-use-of-imaging-surveillance-at-2024-asco-annual-meeting
Castle Biosciences Presents New Data Highl...
05/30/2024 21:01:03

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of pa...

castle-biosciences-announces-publication-of-study-demonstrating-decisiondx-scc-test-identifies-high-risk-scc-patients-benefiting-most-from-art
Castle Biosciences Announces Publication O...
05/29/2024 20:32:22

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test,...

castle-biosciences-expands-evidence-supporting-the-performance-of-its-tissuecypher-barretts-esophagus-test-in-predicting-future-development-of-esophageal-cancer
Castle Biosciences Expands Evidence Suppor...
05/14/2024 11:07:01

castle-biosciences-announced-data-from-study-further-for-performance-of-its-decisiondx-um
Castle Biosciences Announced Data From Stu...
05/08/2024 22:42:10

castle-biosciences-says-new-data-supporting-the-utility-of-its-decisiondx-scc-test-in-patients-with-high-risk-cutaneous-squamous-cell-carcinoma-tumors-located-on-the-head-and-neck-hn-will-be-shared-at--56th-american-college-of-mohs-surgery-meeting
Castle Biosciences Says New Data Supportin...
05/03/2024 11:13:15

baird-maintains-outperform-on-castle-biosciences-raises-price-target-to-34
Baird Maintains Outperform on Castle Biosc...
05/03/2024 10:56:48

Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...

castle-biosciences-increases-fy23-revenue-from-235m-240m-to-255m-265m-vs-237636m-est
Castle Biosciences Increases FY23 Revenue ...
05/02/2024 21:34:58

castle-biosciences-q1-2024-gaap-eps-009-beats-033-estimate-sales-72974m-beat-66199m-estimate
Castle Biosciences Q1 2024 GAAP EPS $(0.09...
05/02/2024 20:33:47

Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION